Local-regional therapy plus ICIs, chemotherapy, and lenvatinib versus ICIs plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter study.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) plus chemotherapy serve as the primary treatment for advanced intrahepatic cholangiocarcinoma (ICC), but they present limited effectiveness. This multicenter study intended to evaluate the feasibility of LRT plus ICIs, chemotherapy, and lenvatinib in patients with advanced ICC.

Methods

Patients receiving LRT-ICIs-Chemotherapy-Lenvatinib (LRT-ICI-Chemo-Len group, N = 66) or ICIs-Chemotherapy (ICI-Chemo group, N = 81) between April 2020 and May 2025 were enrolled. The study's outcomes included progression-free survival (PFS), overall survival (OS), tumor response, and adverse events (AEs).

Results

The LRT-ICI-Chemo-Len group showed notable enhancement in median PFS (9.9 months vs. 7.6 months, P = 0.004), median OS (20.9 mon

SUBMITTER: Wang M 

PROVIDER: S-EPMC12847575 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature